Micro-cap biotech Aeglea BioTherapeutics has impressed investors with a rapid pivot into the field of autoimmune disease, with the acquisition of Spyre Therapeutics.
Aeglea Revives Fortunes By Joining Merck And Roivant In TL1A Drug Chase
Spyre Buyout Brings Potential Long-Acting Rivals To IBD Drugs
Aeglea looked to be company running out of time, but the reverse merger with Spyre Therapeutics and its TL1A-based inflammatory bowel disease assets could prove to be an inspired move.
More from Business
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
More from Scrip
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.